|
SAN DIEGO, June 24, 2018 /PRNewswire-USNewswire/ -- Renova Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical model of type 1 diabetes was accepted as a...
Tags
type
american
abstract
presented
Category:
Financial Services
All news |
||||||||||||||||||
|